A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells

BACKGROUND: Apatinib is a newly approved antitumor drug (molecular targeted agent/small molecular kinase inhibitor) for advanced hepatocellular carcinoma (HCC) treatment. However, current oral administration of apatinib could induce the even distribution of drugs in the body and cause the concentrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yanli, Tang, Zigui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278711/
https://www.ncbi.nlm.nih.gov/pubmed/30555243
http://dx.doi.org/10.2147/OTT.S188209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278711/
https://www.ncbi.nlm.nih.gov/pubmed/30555243
http://dx.doi.org/10.2147/OTT.S188209

Ejemplares similares